Lung adenoma

Summary

Lung adenoma (MONDO:0003422) is a cancer. A subtype of lung benign neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	lung adenoma
Mondo ID	MONDO:0003422
DOID	DOID:5386
NCIT	C4455
SNOMED CT	254642004
UMLS	C0345964
MedGen	83394
Anatomy (UBERON)	UBERON:0002048
Is cancer (heuristic)	yes

Also known as: adenoma of lung · adenoma of the lung · lung adenoma · pulmonary adenoma

Disease family

This is a subtype of lung benign neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › respiratory system disorder › respiratory system benign neoplasm › lung benign neoplasm › lung adenoma

Related subtypes (4): hemangioma of lung, lung leiomyoma, clear cell-sugar-tumor of the lung, lung papilloma

Subtypes (2): bronchus adenoma, alveoli adenoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.